+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Schizophrenia Therapeutics Market - Global Forecast 2026-2032- Product Image
Schizophrenia Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Schizophrenia Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6012570
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Schizophrenia Therapeutics Market is projected to reach USD 6.54 Billion in 2026. It is expected to continue growing at a CAGR of 6.47%, reaching USD 9.64 Billion by 2032.

Schizophrenia therapeutics are evolving from symptom-control strategies toward more personalized, function-focused treatment models that address positive symptoms, negative symptoms, cognitive impairment, relapse prevention, and long-term adherence. The therapeutic landscape includes oral antipsychotics, long-acting injectable antipsychotics, adjunctive therapies, psychosocial interventions, digital adherence tools, and emerging mechanisms designed to improve outcomes beyond dopamine D2 receptor modulation. Clinical priorities remain centered on reducing relapse, improving tolerability, supporting recovery-oriented care, and minimizing treatment discontinuation, which is a persistent challenge in schizophrenia management. Demand for improved schizophrenia treatment is being shaped by earlier diagnosis, expanded community mental health programs, greater attention to metabolic and neurological adverse effects, and the need for integrated care across psychiatry, primary care, neurology, and social support systems.

Transformative Shifts in the Schizophrenia Therapeutics Landscape

The schizophrenia therapeutics landscape is undergoing transformative shifts driven by scientific innovation, changing care delivery models, and stronger emphasis on real-world outcomes. Long-acting injectable formulations are gaining importance because nonadherence is a recognized contributor to relapse, hospitalization, and functional decline. Treatment pathways are also shifting toward shared decision-making, where patient preference, side-effect burden, dosing convenience, and psychosocial needs influence therapy selection. Research continues to expand beyond traditional dopamine blockade, with increasing focus on glutamatergic, muscarinic, serotonergic, and inflammatory pathways to address unmet needs such as negative symptoms and cognitive dysfunction. At the same time, health systems are incorporating coordinated specialty care, early psychosis intervention services, telepsychiatry, and community-based support to reduce delays in treatment and improve continuity of care.

Cumulative Impact of Artificial Intelligence on Schizophrenia Therapeutics

Artificial intelligence is increasingly influencing schizophrenia therapeutics by improving clinical trial design, patient stratification, treatment monitoring, pharmacovigilance, and digital mental health workflows. AI-enabled analytics can support earlier detection of relapse risk by analyzing electronic health records, prescription patterns, patient-reported outcomes, speech signals, sleep patterns, activity levels, and other digital biomarkers, although clinical validation and ethical oversight remain essential. In drug development, machine learning is being used to identify novel targets, model disease heterogeneity, optimize trial recruitment, and evaluate treatment response patterns across diverse patient populations. AI also has potential to enhance adherence management through predictive alerts and personalized engagement tools, particularly when integrated with clinician oversight. However, responsible adoption requires safeguards for privacy, bias mitigation, transparency, explainability, and regulatory compliance, especially because schizophrenia care often involves vulnerable populations and complex consent considerations.

Key Regional Insights Across Schizophrenia Therapeutics

In Asia-Pacific, schizophrenia therapeutics are shaped by large population needs, rapid expansion of mental health services, uneven psychiatrist availability, and growing use of digital care models in urban settings. China, India, Japan, South Korea, and Australia are key contributors to clinical adoption patterns, with policy attention increasingly directed toward community-based mental health, earlier psychosis care, and improved access to essential psychotropic medicines. North America remains highly influential in schizophrenia treatment innovation due to advanced clinical research infrastructure, established reimbursement pathways for antipsychotic therapies, broad use of long-acting injectables, and integration of behavioral health with primary care. In Latin America, access to schizophrenia therapeutics varies across public and private systems, while Brazil and Mexico continue to strengthen mental health coverage, hospital-to-community transition models, and essential medicine availability. Europe demonstrates strong regulatory oversight, guideline-driven prescribing, pharmacovigilance systems, and growing prioritization of early intervention services, with the European Union supporting cross-border mental health policy alignment and medicines safety standards. The Middle East is expanding psychiatric infrastructure and mental health awareness, particularly in Gulf countries where national health transformation programs are improving specialty care access and digital health adoption. Africa faces significant treatment gaps driven by workforce shortages, stigma, supply chain constraints, and limited specialist coverage; however, task-sharing models, community health programs, and essential medicine policies are increasingly important for improving access to schizophrenia treatment.

Key Group Insights Shaping Schizophrenia Therapeutics

Across ASEAN, schizophrenia therapeutics are influenced by diverse healthcare financing systems, rising mental health awareness, and the need to strengthen psychiatric workforce capacity while improving access to antipsychotic medicines beyond major cities. The GCC is advancing mental health modernization through national health strategies, investment in specialty services, and broader acceptance of digital health tools that can support adherence, follow-up care, and continuity after hospitalization. Within the European Union, harmonized pharmacovigilance expectations, robust clinical guidelines, and national reimbursement frameworks shape the adoption of schizophrenia treatments, while early psychosis intervention and community-based care remain major priorities. BRICS countries reflect substantial heterogeneity: China, India, Brazil, Russia, and South Africa each face different access, affordability, workforce, and service delivery challenges, yet all are relevant to global schizophrenia care because of large patient populations and expanding health system capacity. G7 countries generally demonstrate stronger research ecosystems, advanced regulatory structures, and wider availability of innovative antipsychotic formulations, although disparities in access, adherence support, and continuity of care persist within many high-income settings. NATO member countries overlap significantly with high-income healthcare systems in North America and Europe, where schizophrenia therapeutics are shaped by national formularies, defense and veteran health systems, crisis care reforms, and efforts to reduce hospitalization through integrated community support.

Key Country Insights in Schizophrenia Therapeutics

The United States is a major center for schizophrenia therapeutics innovation, with strong clinical trial activity, broad availability of branded and generic antipsychotics, and increasing focus on long-acting injectables, early psychosis programs, crisis care redesign, and value-based behavioral health care. Canada emphasizes publicly supported access, guideline-based prescribing, and integrated mental health services, though geographic disparities affect remote and Indigenous communities. Mexico is improving psychiatric care access through public health initiatives, but affordability, continuity of treatment, and specialist access remain important considerations. Brazil has a large public health system that supports essential medicines and community psychosocial care, while treatment access can vary by region. In the United Kingdom, schizophrenia therapeutics are shaped by evidence-based guidelines, early intervention services, structured assessment of treatment-resistant schizophrenia, and careful monitoring of medication-related adverse effects. Germany, France, Italy, and Spain demonstrate mature regulatory and reimbursement environments, with emphasis on pharmacovigilance, specialist-led prescribing, long-acting injectable use where clinically appropriate, and community care models, although service capacity varies by locality. Russia has longstanding psychiatric infrastructure, and treatment approaches continue to be influenced by national clinical practice frameworks and public sector access. China is expanding mental health service capacity, strengthening psychiatric hospitals and community programs, and increasing research activity in neuropsychiatric disorders. India faces high unmet need due to workforce shortages and urban-rural disparities, but telepsychiatry, essential medicine programs, and public mental health initiatives are improving reach. Japan has a well-established psychiatric care system with strong attention to medication safety, aging-related comorbidity, and long-term treatment continuity. Australia supports guideline-based schizophrenia care through public mental health services, early psychosis programs, psychosocial rehabilitation, and digital mental health integration. South Korea combines advanced healthcare infrastructure with growing policy attention to mental health access, stigma reduction, suicide prevention, and long-term management of severe mental illness.

Actionable Recommendations for Schizophrenia Therapeutics Leaders

Industry leaders should prioritize schizophrenia therapeutics strategies that improve adherence, tolerability, and functional outcomes while addressing the full spectrum of symptoms. Development programs should include diverse populations, real-world evidence generation, patient-reported outcomes, and endpoints that capture relapse prevention, cognition, negative symptoms, quality of life, and caregiver burden. Stakeholders should strengthen partnerships with healthcare systems to support long-acting injectable access, early psychosis intervention, community-based continuity of care, integrated metabolic monitoring, and coordinated support for treatment-resistant schizophrenia. Digital and AI-enabled tools should be deployed with clinical validation, privacy safeguards, and bias controls to enhance rather than replace clinician judgment. Leaders should also align access strategies with local treatment guidelines, essential medicine lists, reimbursement requirements, and regional mental health policy priorities. Education for clinicians, patients, and caregivers should focus on shared decision-making, side-effect management, adherence planning, relapse prevention, and stigma reduction.

Research Methodology for Schizophrenia Therapeutics Analysis

This executive summary is developed using a structured secondary research approach focused on verified and publicly available information from clinical guidelines, regulatory publications, peer-reviewed medical literature, public health sources, pharmacovigilance frameworks, and mental health policy documents. The methodology emphasizes evidence triangulation across epidemiology references, treatment guidelines, drug class information, care delivery models, and regional health system policies. Insights were assessed for clinical relevance, geographic applicability, regulatory context, and consistency with established schizophrenia management principles. The analysis excludes market sizing, market share, and forecasting, and focuses instead on therapeutic trends, regional access dynamics, innovation drivers, health system implications, and strategic considerations for schizophrenia treatment stakeholders.

Conclusion: Advancing Patient-Centered Schizophrenia Therapeutics

Schizophrenia therapeutics are entering a more integrated and innovation-driven phase, where clinical success depends on combining effective antipsychotic therapy with adherence support, early intervention, digital monitoring, psychosocial care, and patient-centered decision-making. Advances in novel mechanisms, long-acting formulations, AI-enabled analytics, and coordinated care models are reshaping how schizophrenia is treated across regions. However, persistent challenges-including stigma, delayed diagnosis, side-effect burden, limited specialist access, and inconsistent treatment continuity-continue to affect outcomes. Stakeholders that focus on clinically validated innovation, equitable access, evidence-based care pathways, and real-world patient needs will be best positioned to advance schizophrenia therapeutics and improve long-term recovery outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Schizophrenia Therapeutics Market, by Type
7.1. Introduction
7.2. Non-Pharmacological Therapies
7.2.1. Cognitive-Behavioral Therapy (CBT)
7.2.2. Electroconvulsive Therapy (ECT)
7.2.3. Family Therapy
7.3. Pharmacological Therapies
7.3.1. Injectable Medications
7.3.2. Oral Medications
8. Schizophrenia Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Antipsychotics
8.2.1. First-Generation Antipsychotics
8.2.2. Second-Generation Antipsychotics
8.3. Mood Stabilizers
8.4. Selective Serotonin Reuptake Inhibitors
9. Schizophrenia Therapeutics Market, by Mechanism of Action
9.1. Introduction
9.2. Dopamine Receptor Antagonists
9.3. Glutamate Modulators
9.4. Serotonin Dopamine Activity Modulators
10. Schizophrenia Therapeutics Market, by Formulation Type
10.1. Introduction
10.2. Inserts and Patches
10.3. Liquid Solutions
10.4. Solid Tablets
11. Schizophrenia Therapeutics Market, by End Users
11.1. Introduction
11.2. Homecare Settings
11.3. Hospitals
11.4. Mental Health Clinics
11.5. Research Institutes
12. Schizophrenia Therapeutics Market, by Patient Settings
12.1. Introduction
12.2. Inpatient Care
12.3. Outpatient Care
13. Schizophrenia Therapeutics Market, by Patient Demographics
13.1. Introduction
13.2. Adult Patients
13.3. Geriatric Patients
13.4. Pediatric Patients
14. Schizophrenia Therapeutics Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Schizophrenia Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Schizophrenia Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc.
18.2. Acadia Pharmaceuticals Inc.
18.3. Alkermes Plc
18.4. Amneal Pharmaceuticals, LLC
18.5. Astellas Pharma Inc.
18.6. AstraZeneca plc
18.7. BioXcel Therapeutics, Inc.
18.8. Boehringer Ingelheim International GmbH
18.9. Bristol Myers Squibb Company
18.10. Cipla Limited
18.11. Delpor, Inc.
18.12. Dr. Reddy’s Laboratories Ltd.
18.13. Eli Lilly and Company
18.14. Gedeon Richter Plc
18.15. GlaxoSmithKline plc.
18.16. Glenmark Pharmaceuticals Limited
18.17. Johnson & Johnson Services, Inc.
18.18. Lundbeck A/S
18.19. Lupin Limited
18.20. Luye Pharma Group Ltd
18.21. Lyndra Therapeutics Inc
18.22. Meiji Holdings Co., Ltd.
18.23. Merck & Co., Inc.
18.24. Neurocrine Biosciences, Inc.
18.25. Novartis AG
18.26. Otsuka Holdings Co., Ltd.
18.27. Pfizer Inc.
18.28. Reviva Pharmaceuticals Holdings, Inc.
18.29. Sanofi S.A
18.30. Sumitomo Pharma Co., Ltd.
18.31. Sun Pharmaceutical Industries Limited
18.32. Takeda Pharmaceutical Company Limited
18.33. Teva Pharmaceutical Industries Ltd.
18.34. Torrent Pharmaceuticals Ltd.
18.35. Vanda Pharmaceuticals Inc.
List of Figures
FIGURE 1. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025 VS 2032 (%)
FIGURE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2032 (%)
FIGURE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NON-PHARMACOLOGICAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL COGNITIVE-BEHAVIORAL THERAPY (CBT) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL COGNITIVE-BEHAVIORAL THERAPY (CBT) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL COGNITIVE-BEHAVIORAL THERAPY (CBT) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ELECTROCONVULSIVE THERAPY (ECT) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ELECTROCONVULSIVE THERAPY (ECT) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ELECTROCONVULSIVE THERAPY (ECT) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL FAMILY THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL FAMILY THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL FAMILY THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PHARMACOLOGICAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PHARMACOLOGICAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PHARMACOLOGICAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL INJECTABLE MEDICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INJECTABLE MEDICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INJECTABLE MEDICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ORAL MEDICATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MOOD STABILIZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MOOD STABILIZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MOOD STABILIZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL DOPAMINE RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL DOPAMINE RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL DOPAMINE RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL GLUTAMATE MODULATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL GLUTAMATE MODULATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL GLUTAMATE MODULATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SEROTONIN DOPAMINE ACTIVITY MODULATORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SEROTONIN DOPAMINE ACTIVITY MODULATORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SEROTONIN DOPAMINE ACTIVITY MODULATORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL INSERTS AND PATCHES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INSERTS AND PATCHES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INSERTS AND PATCHES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL LIQUID SOLUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL LIQUID SOLUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL LIQUID SOLUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SOLID TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SOLID TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SOLID TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL MENTAL HEALTH CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MENTAL HEALTH CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL MENTAL HEALTH CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL INPATIENT CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL INPATIENT CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL INPATIENT CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL OUTPATIENT CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL OUTPATIENT CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL OUTPATIENT CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 125. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 127. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 128. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 129. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 130. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 131. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 132. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 133. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 134. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 135. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 147. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 149. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 150. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 151. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 152. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 153. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 154. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 155. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 156. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 157. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 161. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 162. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 163. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 164. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 165. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 166. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 167. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 168. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 169. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 170. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 172. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 173. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 174. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 175. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 176. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 177. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 178. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 179. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 180. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 192. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 193. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 194. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 195. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 196. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 197. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 198. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 199. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 200. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 201. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 202. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 203. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 205. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 206. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 207. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 208. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 209. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 210. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 211. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 212. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 213. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 214. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 216. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 217. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 218. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 219. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 220. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 221. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 222. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 223. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 224. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 225. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 226. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 228. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 237. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 239. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 240. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 241. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 242. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 243. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 244. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 245. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 246. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 247. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 248. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 249. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 250. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 251. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 252. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 253. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 254. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 255. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 256. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 257. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 258. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 259. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 261. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 262. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 263. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 264. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 265. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 266. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 267. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 270. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 271. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 281. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 283. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 284. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 285. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 286. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 287. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 288. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 289. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 290. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 291. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 292. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 293. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 294. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 295. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 296. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 297. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 298. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 299. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 300. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 301. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 302. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 303. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 306. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 307. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 308. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 309. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 310. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 311. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 312. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 313. RUSSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 314. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 315. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 316. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 317. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 318. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2017-2032 (USD MILLION)
TABLE 319. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2017-2032 (USD MILLION)
TABLE 320. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2017-2032 (USD MILLION)
TABLE 321. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 322. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 323. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2017-2032 (USD MILLION)
TABLE 324. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 325. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 326. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 327. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 328. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 329. SPAIN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS,

Companies Mentioned

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Delpor, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline plc.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sanofi S.A
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.54 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.64 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned35

Related Topics

Related Reports

Schizophrenia Drugs Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Image

Schizophrenia Drugs Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Schizophrenia Drugs Market Outlook 2026-2034: Market Share, and Growth Analysis by Therapeutic Class, Drug Mechanism of Action, Treatment Type, Distribution Channel - Product Image

Schizophrenia Drugs Market Outlook 2026-2034: Market Share, and Growth Analysis by Therapeutic Class, Drug Mechanism of Action, Treatment Type, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Schizophrenia Therapeutics - Global Strategic Business Report - Product Image

Schizophrenia Therapeutics - Global Strategic Business Report

  • Report
  • 236 Pages
  • Global
From
Antipsychotic Drugs Market - Global Forecast 2026-2032 - Product Image

Antipsychotic Drugs Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Ziprasidone Mesylate for Injection Market - Global Forecast 2026-2032 - Product Image

Ziprasidone Mesylate for Injection Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.